Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTX-COVID19-B vs Pfizer-BioNTech COVID-19 Vaccine in Healthy Adults
NCT05175742Phase 2Completed
- Sponsor
- Providence Therapeutics
- Start
- Aug 2021
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of PTX-COVID19-B in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Providence Therapeutics. Primary endpoints: Injection Site Reactions at Day 42, Incidence of Solicited Adverse Events at Day 7 and 4 more. Started Aug 2021; status: completed.
02
Drugs
PTX-COVID19-B
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05175742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05175742.